about
Controversies in targeted therapy of adult T cell leukemia/lymphoma: ON target or OFF target effects?How animal models of leukaemias have already benefited patientsExtracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studiesSinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT)Acellular bone marrow extracts significantly enhance engraftment levels of human hematopoietic stem cells in mouse xeno-transplantation modelsReducing the global burden of HTLV-1 infection: An agenda for research and action.Tax-1 and Tax-2 similarities and differences: focus on post-translational modifications and NF-κB activation.Signet ring-like light chain myeloma with systemic spread.Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center.Tax ubiquitylation and sumoylation control critical cytoplasmic and nuclear steps of NF-kappaB activation.Bone marrow mesenchymal stem cell transplantation in patients with multiple sclerosis: a pilot study.miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.The central region of human T-cell leukemia virus type 1 Tax protein contains distinct domains involved in subunit dimerizationTreatment of adult T-cell leukaemia/lymphoma: current strategy and future perspectives.Therapy-induced selective loss of leukemia-initiating activity in murine adult T cell leukemiaDistribution of killer cell immunoglobulin-like receptor (KIR) genotypes in patients with familial Mediterranean fever.Combination of arsenic and interferon-α inhibits expression of KSHV latent transcripts and synergistically improves survival of mice with primary effusion lymphomasPersistent inhibition of telomerase reprograms adult T-cell leukemia to p53-dependent senescence.A Transgenic Drosophila melanogaster Model To Study Human T-Lymphotropic Virus Oncoprotein Tax-1-Driven Transformation In Vivo.New therapeutic approaches for adult T-cell leukaemia.Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007.Adult T-Cell Leukemia/Lymphoma in a Caucasian Patient After Sexual Transmission of Human T-Cell Lymphotropic Virus Type 1.Low nuclear body formation and tax SUMOylation do not prevent NF-kappaB promoter activationA case of successful double sequential bone marrow and kidney transplantations in a patient with multiple myeloma.An overview of the pathogenesis and natural history of post-transplant T-cell lymphoma (corrected and republished article originally printed in Leukemia & Lymphoma, June 2007; 48(6): 1237 - 1241).Adult T cell leukaemia: a review of established and new treatments.Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.The combination of arsenic, interferon-alpha, and zidovudine restores an "immunocompetent-like" cytokine expression profile in patients with adult T-cell leukemia lymphoma.Hematopoietic stem cell transplantation in Lebanon: first comprehensive report.Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease.Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting.Emerging role of CD20 blockade in allogeneic hematopoietic cell transplantation.The multifaceted oncoprotein Tax: subcellular localization, posttranslational modifications, and NF-κB activation.The drug-induced degradation of oncoproteins: an unexpected Achilles' heel of cancer cells?Animal models on HTLV-1 and related viruses: what did we learn?Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies.Therapeutic options for adult T-cell leukemia/lymphoma.Primary effusion lymphoma in an elderly patient effectively treated by lenalidomide: case report and review of literature.Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
P50
Q26852683-E9BF4BAB-A2FF-4862-8651-D0C00ED2EDEFQ26997702-545A7622-9C5C-4A92-BE20-E3045DA9CA06Q27006971-349976E4-46A2-495B-9518-1C3AB9EF8DC3Q28083417-D9A7B8DA-B7A3-42DB-9622-5F98BC8B35E6Q28727639-EE24D3B9-8568-41A1-8E70-2436834BEEACQ30241350-897A17F8-1217-49DB-95B4-459A44BB45BEQ30353061-5DA3B7A8-1F15-4533-82C3-B362B5FE00D8Q33347143-1A335D85-A92B-47F6-B756-802D90F99264Q33363304-69B2D0B4-4687-40E5-BF65-CEE033A31BBDQ33992995-9B8EFBC2-6CC4-4E1D-A7D6-09A7241D9D42Q34132522-1CD5E368-8CE2-4076-A0A8-314ADD93C6F3Q34215056-DBE11C8D-7922-4CB6-9937-3019B989FE90Q34227299-085F89B6-9F57-4584-AB64-1F636A44FA0FQ34345302-F8A120B9-29C7-4385-BC8A-33008AD12864Q34420787-BB59CC41-B873-4D4B-B384-649DD328F341Q34967760-40F928BF-5BFF-43FD-8A7F-0474B6B9917AQ35046691-CBDC4F02-6BE9-44DA-BD72-59126B2EFD63Q35849897-33150E6B-03EB-4C1C-8CF1-778A760CEF42Q35861179-914FE685-82CE-468B-9539-D564CC487E3CQ35937446-BA16B566-B4C4-4AD6-A33D-3034F3527A8CQ36020073-D25F55B8-83B7-470F-8FC8-190A936A4A28Q36051921-AF4C89BA-A02B-49B6-B43B-45150B1C88CBQ36334848-3090A6AB-2FA8-4026-8987-B0B942B2B9AAQ36591880-5C51116E-468A-40A3-8FCE-17938A9A8044Q36929679-35BD317C-E1D4-4555-B2D8-DAE6DBB76C02Q37004559-6BBAAEAC-5A8C-490C-9E78-9B10FD127E39Q37073000-2461A0A1-E11F-4DEB-9D43-67451780F5A2Q37116770-383B85DC-7451-4905-BA99-DE27F42EBFB4Q37251071-17972906-46F1-4D07-84CA-B024A3EF231EQ37254940-DF9DD164-C356-4168-9C11-ACCE13D02C45Q37331991-E912E1B3-F719-4EA6-8A64-E1E4EEB39740Q37677276-303087E1-5499-4391-B3A2-BE8D533DA46EQ37994930-79CC6E70-4745-41C5-BB7E-640E4AF4B521Q38010165-9B9B419A-58D3-4299-AB9E-5F9A14B8CEAAQ38050763-1E7E8139-445A-43B6-ADA1-FCE1E1A99B8AQ38103578-9C9A4622-5557-4A51-A3FD-180FF9EF388BQ38128790-AEC68D65-0456-49B9-ADBA-4D0D9C486F26Q38194434-82C523A0-5129-4990-B363-A81269B4078BQ38200909-F53DC642-510C-49E6-9EC2-C6F04D1240FEQ38271855-C5E7706B-13AD-4942-A574-1E80C13632C2
P50
description
researcher, ORCID id # 0000-0002-7171-4997
@en
wetenschapper
@nl
name
Ali Bazarbachi
@ast
Ali Bazarbachi
@en
Ali Bazarbachi
@es
Ali Bazarbachi
@nl
type
label
Ali Bazarbachi
@ast
Ali Bazarbachi
@en
Ali Bazarbachi
@es
Ali Bazarbachi
@nl
prefLabel
Ali Bazarbachi
@ast
Ali Bazarbachi
@en
Ali Bazarbachi
@es
Ali Bazarbachi
@nl
P106
P1153
7006517199
P21
P31
P496
0000-0002-7171-4997